Nobuya Hamanoue

Activation of overexpressed glucagon‐like peptide‐1 receptor attenuates prostate cancer growth by inhibiting cell cycle progression

Toru Shigeoka, Takashi Nomiyama, Takako Kawanami, Yuriko Hamaguchi et autres

AIMS/INTRODUCTION: Incretin therapy is a common treatment for type 2 diabetes mellitus. We have previously reported an anti-prostate cancer effect of glucagon-like peptide-1 receptor (GLP-1R) agonist exendin-4. The attenuation of cell proliferation in the prostate cancer cell line was dependent on GLP-1R …

jp (code pays fourni par la source)

Relatively low sex hormone‐binding globulin concentration is a risk factor for hyperuricemia in middle‐aged Japanese men

Yuya Fujihara, Nobuya Hamanoue, Yuko Akehi, Ryoko Motonaga et autres

Summary Objective Low testosterone and hyperuricemia are associated with metabolic syndrome (MetS). However, little is known about the nature of the relationships between serum testosterone and sex hormone‐binding globulin (SHBG) concentrations, and hyperuricemia. Methods We evaluated the relationships between serum testosterone (calculated …

jp (code pays fourni par la source)

Efficacy and safety of a combination of an insulin secretagogue and a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes mellitus; the repaglinide glucose oscillation study in Fukuoka (REGO-F)

Yuichi Terawaki, Chikayo Iwaya, Takashi Nomiyama, Dai Shimono et autres

jp (code pays fourni par la source)

SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation

Shiho Komatsu, Takashi Nomiyama, Tomohiro Numata, Takako Kawanami et autres

Cancer is currently one of the major causes of death in patients with type 2 diabetes mellitus. We previously reported the beneficial effects of the glucagon-like peptide-1 receptor agonist exendin-4 against prostate and breast cancer. In the present study, we examined the …

jp (code pays fourni par la source)

SUN-026 Selective Androgen Receptor Modulator S42 Has Anabolic and Anti-Catabolic Effects on Cultured Myotubes

Yoshimi Muta, Tomoko Tanaka, Yuriko Hamaguchi, Nobuya Hamanoue et autres

Introduction: In an effort to develop a selective androgen receptor modulator (SARM) with beneficial activity in energy homeostasis, we previously screened 119 steroid analogs for the ability to induce uncoupling protein-1 (UCP-1) mRNA without increasing prostate-specific antigen promoter activity in human prostate …

jp (code pays fourni par la source)

Selective androgen receptor modulator, S42 has anabolic and anti-catabolic effects on cultured myotubes

Yoshimi Muta, Tomoko Tanaka, Yuriko Hamaguchi, Nobuya Hamanoue et autres

We previously identified a novel selective androgen receptor modulator, S42, that does not stimulate prostate growth but has a beneficial effect on lipid metabolism. S42 also increased muscle weight of the levator ani in orchiectomized Sprague–Dawley rats. These findings prompted us to …

jp (code pays fourni par la source)

High sex hormone-binding globulin concentration is a risk factor for high fibrosis-4 index in middle-aged Japanese men

Yuya Fujihara, Nobuya Hamanoue, Hiromi Yano, Makito Tanabe et autres

Low endogenous testosterone and sex hormone-binding globulin (SHBG) concentrations have been reported to be associated with metabolic syndrome (MetS) and non-alcoholic fatty liver disease (NAFLD). However, little is known about the relationships between testosterone or SHBG and liver fibrosis in NAFLD. Thus, …

jp (code pays fourni par la source)

A higher score on the Aging Males’ Symptoms scale is associated with insulin resistance in middle-aged men

Nobuya Hamanoue, Makito Tanabe, Tomoko Tanaka, Yuko Akehi et autres

An age-associated androgen decrease and its pathological conditions are defined as late-onset hypogonadism (LOH). Among the various symptoms associated with LOH, a visceral fat increase is strongly associated with relatively low levels of testosterone. However, few studies have investigated the relationship between …

jp (code pays fourni par la source)

The efficacy of incretin therapy in patients with type 2 diabetes undergoing hemodialysis

Yuichi Terawaki, Takashi Nomiyama, Yuko Akehi, Hiromasa Takenoshita et autres

BACKGROUND: Although incretin therapy is clinically available in patients with type 2 diabetes undergoing hemodialysis, no study has yet examined whether incretin therapy is capable of maintaining glycemic control in this group of patients when switched from insulin therapy. In this study, …

jp (code pays fourni par la source)